The four mechanisms killing motor neurons
Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
ALS is not one broken part. It is four failures that feed each other, and that is the honest reason thirty years of drug development has produced so little.
Each mechanism has been targeted. Each targeted drug has helped modestly or not at all, because the others continue.
Related pages: ALS (amyotrophic lateral sclerosis)
The bottom line
- TDP-43 leaves the nucleus and clumps in the cytoplasm in the large majority of cases.
- Glutamate is not cleared properly from around motor neurons, over-exciting them.
- Mitochondria fail in cells with exceptional energy demands.
- Transport along the axon breaks down, and microglia shift from support to attack.
- Which mechanism comes first, and whether that differs between people.
- Why motor neurons specifically are vulnerable when these mechanisms are general.
The story, step by step
- 1. TDP-43 ()
- 2. Glutamate ()
- 3. Energy ()
- 4. Transport ()
- 5. The neighbours ()
What the evidence labels mean
A protein in the wrong place
What happens
This is the most consistent finding in ALS and the most important discovery in the field since the 1990s.
What the research shows
- TDP-43 is a protein that normally lives in the cell nucleus, where it manages RNA: which genes are read, how their messages are edited and spliced.
- In ALS it leaves the nucleus, accumulates in the cytoplasm, and clumps into insoluble aggregates.
- This causes two problems at once: toxic clumps where they should not be, and the loss of an essential nuclear function.
- Without properly managed RNA, the cell cannot build the proteins it needs, including those maintaining the axon and the synapse.
- TDP-43 pathology is found in the large majority of ALS cases, and also in a form of frontotemporal dementia, which is part of why the two conditions overlap.
Why it matters
TDP-43 is the link between ALS and frontotemporal dementia, and it is why the two are now understood as a spectrum rather than separate diseases.
What's still uncertain
- Cases caused by SOD1 and FUS mutations generally do not show TDP-43 pathology, so it is not universal.
Read more
- NINDS: Amyotrophic lateral sclerosis (ALS)Government
- OwieClear: Frontotemporal dementiaOwieClear
Next: Glutamate
Too much signal, not enough clearing
What happens
Motor neurons are killed in part by the very signal they exist to receive.
What the research shows
- Glutamate is the main excitatory neurotransmitter. After a signal, it must be cleared from the synapse quickly.
- Astrocytes, the support cells, do that clearing using a transporter called EAAT2.
- In ALS, EAAT2 levels are reduced and clearance fails, leaving glutamate lingering around the motor neuron.
- Persistent stimulation lets calcium flood into the cell, and sustained high calcium triggers damaging enzyme cascades and free radical production.
- Motor neurons are particularly vulnerable because they have relatively low capacity to buffer calcium compared with other neurons.
Why it matters
Riluzole, the first approved ALS drug, acts on this mechanism. It helps, modestly, which tells you both that the mechanism is real and that it is not the whole story.
What's still uncertain
- Whether excitotoxicity is a primary driver or a consequence of other failures is debated.
Read more
- NINDS: Amyotrophic lateral sclerosis (ALS)Government
- OwieClear: Treatments and breathing supportOwieClear
Next: Energy
Mitochondria in the most demanding cell in the body
What happens
Motor neurons have an unusual energy problem.
What the research shows
- Firing signals repeatedly along an axon up to a metre long consumes enormous amounts of ATP.
- Mitochondria must be manufactured in the cell body and transported the entire length of the axon to where they are needed.
- In ALS, mitochondria show structural abnormalities, produce less energy, and leak reactive oxygen species.
- Those free radicals damage lipids, proteins and DNA inside the cell, adding to the burden.
- The SOD1 gene, the first ALS gene identified in 1993, codes for an enzyme that neutralizes one class of free radical, which is why oxidative stress has been a focus ever since.
Why it matters
Edaravone, the second approved drug, targets free radical damage. Like riluzole, its effect is modest, for the same reason.
What's still uncertain
- Whether mitochondrial failure is cause or consequence has not been settled.
Read more
Next: Transport
The tracks break down
What happens
A cell this long depends entirely on an internal delivery system.
What the research shows
- Microtubules act as rails along which motor proteins carry cargo: mitochondria, proteins, signalling molecules, in both directions.
- In ALS this transport system is disrupted, and cargo does not reach the far end of the axon.
- The neuromuscular junction, at the end of the line, is the first to be starved of what it needs. That fits the dying-back pattern.
- Several ALS genes, including those causing rarer familial forms, directly affect the transport machinery, which strengthens the case that this is causal.
- Damaged material also fails to travel back to the cell body for disposal, so waste accumulates.
Why it matters
A delivery failure explains why the furthest point fails first, which is exactly what is observed.
What's still uncertain
- How much transport failure contributes relative to the other mechanisms is unknown.
Read more
Next: The neighbours
When support cells join in
What happens
Motor neurons do not die alone, and the cells around them are not passive.
What the research shows
- Astrocytes, which normally support neurons and clear glutamate, become dysfunctional and can actively harm motor neurons in laboratory models.
- Microglia, the brain's immune cells, shift from a housekeeping role to a chronically inflammatory one, releasing damaging signals.
- Experiments in animal models show that healthy support cells can slow disease progression even when the motor neurons carry a disease-causing mutation.
- That finding reframed ALS as a disease of a neighbourhood rather than of one cell type.
- It also opens a different treatment avenue: changing the environment rather than fixing the neuron.
Why it matters
The finding that support cells matter this much is the main reason the field broadened beyond the motor neuron itself.
What's still uncertain
- Immune-modulating treatments have not yet produced a clinically meaningful benefit in trials.
Read more
- NINDS: Amyotrophic lateral sclerosis (ALS)Government
- OwieClear: Where ALS comes fromOwieClear